Janux Therapeutics JANX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's free cash flow?
- Janux Therapeutics (JANX) reported free cash flow of -$12.61M in Q1 2026.
- How has Janux Therapeutics's free cash flow changed year-over-year?
- Janux Therapeutics's free cash flow increased by 27.5% year-over-year, from -$17.4M to -$12.61M.
- What is the long-term trend for Janux Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Janux Therapeutics's free cash flow has grown at a 45.7% compound annual growth rate (CAGR), from -$18.46M to -$83.28M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.